Tonix Pharmaceuticals Holding (TNXP) EBIAT (2023 - 2025)
Historic EBIAT for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$31.8 million.
- Tonix Pharmaceuticals Holding's EBIAT fell 10102.29% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.7 million, marking a year-over-year increase of 3109.61%. This contributed to the annual value of -$136.7 million for FY2024, which is 1718.1% down from last year.
- Tonix Pharmaceuticals Holding's EBIAT amounted to -$31.8 million in Q3 2025, which was down 10102.29% from -$27.4 million recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's EBIAT's 5-year high stood at -$15.8 million during Q3 2024, with a 5-year trough of -$77.3 million in Q2 2024.
- Its 3-year average for EBIAT is -$29.7 million, with a median of -$27.3 million in 2023.
- Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's EBIAT was 6462.14% (2025), while the steepest drop was 10102.29% (2025).
- Tonix Pharmaceuticals Holding's EBIAT (Quarter) stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then crashed by 41.62% to -$31.8 million in 2025.
- Its EBIAT was -$31.8 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$16.1 million in Q1 2025.